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Abstract
Background: Infantile hemangiomas (IHs) are the most common benign tumor of infancy, yet their pathogenesis
is poorly understood. IHs are believed to originate from a progenitor cell, the hemangioma stem cell (HemSC).
Recent studies by our group showed that NOTCH proteins and NOTCH ligands are expressed in hemangiomas,
indicating Notch signaling may be active in IHs. We sought to investigate downstream activation of Notch
signaling in hemangioma cells by evaluating the expression of the basic HLH family proteins, HES/HEY, in IHs.
Materials and Methods: HemSCs and hemangioma endothelial cells (HemECs) are isolated from freshly resected
hemangioma specimens. Quantitative RT-PCR was performed to probe for relative gene transcript levels
(normalized to beta-actin). Immunofluorescence was performed to evaluate protein expression. Co-localization
studies were performed with CD31 (endothelial cells) and NOTCH3 (peri-vascular, non-endothelial cells). HemSCs
were treated with the gamma secretase inhibitor (GSI) Compound E, and gene transcript levels were quantified
with real-time PCR.
Results: HEY1, HEYL, and HES1 are highly expressed in HemSCs, while HEY2 is highly expressed in HemECs. Protein
expression evaluation by immunofluorescence confirms that HEY2 is expressed by HemECs (CD31+ cells), while
HEY1, HEYL, and HES1 are more widely expressed and mostly expressed by perivascular cells of hemangiomas.
Inhibition of Notch signaling by addition of GSI resulted in down-regulation of HES/HEY genes.
Conclusions: HES/HEY genes are expressed in IHs in cell type specific patterns; HEY2 is expressed in HemECs and
HEY1, HEYL, HES1 are expressed in HemSCs. This pattern suggests that HEY/HES genes act downstream of Notch
receptors that function in distinct cell types of IHs. HES/HEY gene transcripts are decreased with the addition of a
gamma-secretase inhibitor, Compound E, demonstrating that Notch signaling is active in infantile hemangioma
cells.
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Background
Infantile hemangiomas (IHs) are the most common
benign tumors of infancy. Despite their prevalence, the
pathogenesis of IHs is not well understood. IHs are
characterized by three phases: proliferating, involuting
and involuted phases. These are defined by a period of
rapid proliferation of blood vessels in the first year of
life, followed by gradual regression of the vascular com-
ponent with replacement by fibro-fatty tissue.[1,2]
The Notch family of proteins function as cell surface
receptors, is highly conserved over multiple species, and
is involved in cell fate determination during embryogen-
esis.[3] Notch genes function critically in angiogenesis
and arteriogenesis.[4-8] The Notch family of genes con-
sists of four Notch receptors (Notch1, -2, -3, and -4),
[9-13] as well as two classes of ligands, Delta-like (Dll-1,
-3, -4),[14-16] and Jagged (Jagged-1, -2)[17,18].
Previous work in our laboratory has shown that mem-
bers of the Notch signaling pathway, namely receptors
and ligands, are expressed in hemangiomas.[19] In parti-
cular, we have demonstrated that the endothelial-asso-
ciated NOTCH1, NOTCH4,a n dJAGGED-1 genes are
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HemECs, while DELTA-LIKE LIGAND-4 (Dll4) showed
an intermediate level of expression in HemECs. In con-
trast, NOTCH3, normally expressed in vascular smooth
muscle cells, was found expressed in HemSCs. More-
over, studies by immunofluorescence showed that
NOTCH1 and NOTCH4 were expressed in HemECs,
whereas NOTCH3 was present in perivascular cells in
IH tissue.[20]
The purpose of this study is to evaluate the expression
of downstream effector genes of Notch signaling, specifi-
cally the HES and HEY family of transcription factors.
HES/HEY genes are part of the hairy enhancer of split
related (HESR) family of genes and encode basic helix-
loop-helix proteins that function as transcriptional
repressors. After activation by binding to its ligand, the
transmembrane Notch receptor undergoes cleavage and
release of the intracellular domain (NICD). This NICD
then translocates to the nucleus, where it interacts with
the DNA-binding protein RBPJ. NICD interaction with
RBPJ leads to transcription of Notch target genes. The
primary target genes of Notch signaling are the HES/
HEY family of transcriptional regulators. [21]
We asked whether the expression of HES/HEY tran-
scripts and proteins are found in cell types associated
with IHs, as further evidence for a role for Notch recep-
tor signaling in IHs.
Methods
Preparation of hemangioma specimen
IRB approval for collection of resected hemangiomas
was obtained from Columbia University College of Phy-
sicians & Surgeons (IRB #AAAA9976). Tissues were
either paraffin embedded for sectioning or used immedi-
ately for cell isolation for in vitro experiments.
Cell extraction and isolation
Previous published reports showed that HemSCs
expressed CD90 but did not express CD31.[22]. We char-
acterized HemSCs based upon CD90 expression and lack
of CD31 expression and verified that the isolated
HemSCs expressed high levels of NOTCH3,r e l a t i v et o
mesenchymal stem cells. [20] (MSC, commercially avail-
able from Lonza, Figure 1). HemECs were confirmed by
lack of Notch3 transcripts by qPCR and CD31 positivity
by FACS analysis.
HemSC and HemEC isolation was conducted as pre-
viously described.[22] Briefly, the hemangioma samples
were minced into small pieces with a scalpel and
digested using collagenase (Roche). From this single cell
suspension, cells expressing CD133 were selected using
a magnetic microbead cell sorting system (Miltenyi Bio-
tec), and plated on fibronectin-coated plates in EGM-2
media (Lonza) supplemented with 20% fetal bovine
serum (Invitrogen), penicillin, and streptomycin (Invitro-
gen). CD133 negative cells were plated in the same
manner. These cells were later sorted for endothelial
cells using CD31 antibody-coated magnetic Dynal beads
(Invitrogen). RNA was later isolated from both cell
populations (CD133+, or HemSC, and CD31+, or
HemEC) as described below. Cells were isolated from 3
different patients (H37, H40, and H41). Furthermore,
RNA from isolated, characterized and validated HemSC
and HemEC samples[22] was provided by EB and JB.
RNA isolation and RT-PCR
Total RNA isolation was performed with RNeasy Mini
Prep Kit (Qiagen). Quantity of RNA was determined
with spectrophotometry. cDNA was synthesized by
reverse transcription of 1 microgram of total RNA, per-
formed using the Superscript II system (Invitrogen). All
reverse transcription (RT) reactions were amplified by
PCR to determine expression of beta-actin, to confirm
successful generation of cDNA.
PCR
Primers used were for HEY1, HEY2,a n dHEYL,a n d
HES1, HES3, HES5, HES6, and HES7. HEY1, forward: 5’
ACG AGA ATG GAA ACT TGA GTT C 3’,r e v e r s e :5 ’
AAC TCC GAT AGT CCA TAG CAA G 3’. HEY2,f o r -
ward: 5’ ATG AGC ATA GGA TTC CGA GAG TG 3’,
reverse: 5’ GGC AGG AGG CAC TTC TGA AG 3’.
HEYL,f o r w a r d :5 ’ C A GG A TT C TT T GA T GC C C
GAG 3’,r e v e r s e :5 ’ GAC AGG GC5T GGG CAC TCT
TC 3’. HES1,f o r w a r d :5 ’ CCC AAC GCA GTG TCA
CCT TC 3’, reverse: 5’ TAC AAA GGC GCA ATC
CAA TAT G 3’. HES3,f o r w a r d :5 ’ CAT CAA TGT
GTC ACT GGA GCA G 3’,r e v e r s e :5 ’ CAA GGA GTT
CTG AAG GCT TCT C 3’. HES5,f o r w a r d :5 ’ TCG
CCT CGT CGC CTG TTC 3’, reverse: 5’ CCA CGA
GTA GCC TTC GCT GTA G 3’. HES6,f o r w a r d :5 ’
AGA ACG CCG AAG TGC TGG AG 3’, reverse: 5’
GAA CTG AGT CAG GCT CCT GCT G 3’. HES7,f o r -
ward: 5’ GGA ACC CGA AGC TGG AGA AAG 3’,
reverse: 5’ GCC TCG GAT CTA CCG GCT TG 3’.
Survey PCR was performed as follows with the Eppen-
dorf Mastercycler: initiation with heating to 94°C for 2
minutes followed by 95°C for 45 seconds. The program
then proceeded to cycle at 60°C (1 minute), annealing at
72°C (1 minute) and extension 72°C (5 minutes) for 40
cycles. Mesenchymal stem cells (MSC, Lonza) were used
as controls.
Quantitative Real-time PCR
Real time PCR was performed in triplicate utilizing the
Applied Biosystem 7300 and SYBR Green PCR Master
Mix reagent (Applied Biosystems). Primers used were
described in the above section.
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Page 2 of 11Figure 1 FACS analysis. (a) FACS analysis results show that HemSCs are positive for CD90 and negative for CD31, consistent with previously
published reports,[22] whereas HemECs are positive for CD31. NOTCH3 expression. (b) qPCR analysis showed that HemSCs express high levels
of NOTCH3, while HemECs showed minimal to no NOTCH3 expression.
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Page 3 of 11The PCR cycler was programmed as follows: initiation
with heating to 50°C for 2 minutes followed by 95°C (2
minutes). The program then proceeded to cycle at 95°C
(15 seconds), annealing at 60°C (40 seconds) and exten-
sion at 72°C (30 seconds) for 50 cycles. The results were
normalized to beta-actin levels and the triplicate results
were averaged for each sample.
DNA from human dermal microvascular endothelial
cells (HDMEC) (isolated from neonatal foreskin as
described for HemECs) and MSCs were used as
controls.
Immunofluorescence
Paraffin-embedded hemangioma specimens were stained
for NOTCH3, (Abcam 23426, rabbit polyclonal, 1:75),
HEY2 (Millipore AB5716, rabbit polyclonal, 1:100) and
HEYL (Millipore MAB10094, mouse monoclonal, 1:250).
The specimens were also co-stained for Notch3 and
HEYL, CD31 (DAKO M0823, mouse monoclonal, 1:20)
and HEY1 (Millipore AB5714, rabbit polyclonal, 1:100),
and CD31 and HES1 (Santa Cruz SC25392, rabbit polyclo-
nal, 1:50), and visualized by immunofluorescence. Briefly,
the slides were de-paraffinized and incubated in blocking
solution containing avidin, biotin, and animal serum. The
blocking agent was removed and the sections were incu-
bated in primary antibody overnight at 4 degrees. The
slides were washed and incubated with secondary antibody
at room temperature for 30 minutes. Slides were then
incubated with immunofluorescent dye (Alexa green 488
or red 594) and Vectashield with DAPI (Vectorlabs) was
applied for visualization of nuclei.
GSI treatment of Hemangioma Stem Cells
H e m S C sw e r eg r o w nt oc o n f l u e n c ei nE G M - 2( L o n z a
EBM-2 with Bullet Kit) supplemented with 20% FBS.
1.5-2 × 10
6 cells were plated in a 10 cm plate and left
overnight at 37°C or until at least 80% confluent. Either
500 nM of compound E (KRICT, South Korea) in 4
microliters, or 4 microliters of vehicle (DMSO) was
added to the plate. RNA was harvested from the control
and treated cells 24 hours later and used for transcript
analysis as described above. Compound E manufactured
by KRICT is equivalent to Compound E from Merck.
Statistical Analysis
For qPCR results, gene expression levels were measured
in triplicate and normalized to beta-actin for an assigned
relative value and standard deviation. Statistical signifi-
cance between 2 samples was calculated using the
unpaired Student’s t-test.
Results
Hemangioma stem cell and endothelial cell expression of
HES and HEY genes
We surveyed HemSC and HemEC samples by RT-PCR
to determine which of the HES/HEY genes are
expressed, including use of HemSC/EC 131 and
HemSC/EC 133 (characterized and provided by EB and
JB).[22] While HES1, -5,a n d-7 have been shown to be
induced by Notch signaling, HES2, -3,a n d-6 are
thought to be Notch independent.[21] Since little is
known about HES4 expression patterns,[23] and no pub-
lished, validated unique primer sets are available for
HES2 and HES4,w ec h o s en o tt oe v a l u a t eHES2 and
HES4.
Our initial survey analysis of expression of HES/HEY
genes in HemSCs and HemECs thus included evaluation
of HES1, HES3, HES5, HES6, HES7, HEY1, HEY2, HEYL.
We found that HEY1, HEY2,a n dHEYL were all
expressed, in HemSCs and HemECs. Of the HES genes
surveyed, only HES1 was expressed, whereas HES3,
HES5, HES6, and HES7 were not (Figure 2). As a result,
Figure 2 Survey PCR for HES gene. PCR analysis showed that
HemSCs showed no expression of HES3, -5, -6, or 7; a very low level
of expression was seen for HES5 in HemECs.
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HES1 only.
We asked whether the expression of HEY1, HEY2,
HEYL and HES1 genes was found in distinct cell types
o fI H s ;H e m S C sa n dH e m E C s .W ef o u n dt h a tH e m S C s
had high relative transcript levels of HEYL and HES1,
when compared to the expression of these genes in
HemECs. In contrast, HemECs expressed HEY2 at
higher levels than HemSCs. The relative transcript levels
of HEY1 between HemSCs and HemECs were not statis-
tically significant (Figure 3).
We used immunoflurescence to evaluate the expres-
sion of HES and HEY proteins in IHs and to confirm
the expression analysis conducted on transcripts levels
in cells derived from IHs. Immunofluorescence studies
showed that HES1, HEY1, HEY2, HEYL were expressed
in IHs (data not shown). In order to further clarify the
staining patterns of these proteins, IH samples were co-
stained with antibodies for HES or HEY and either
CD31, an endothelial cell marker, or NOTCH3, which is
present in non-endothelial peri-vascular cells [20].
Co-staining studies showed that HEY1 was weakly
expressed in cells of both proliferating and involuting
hemangiomas. The HEY1 staining was low and diffuse
throughout the cell. The low level of HEY1 staining did
not co-localize with endothelial cells (Figure 4), and
thus was not deemed to be endothelial-specific, in con-
trast to normal expression of hey1 in murine vascula-
ture.[24,25]
Evaluation of HEY2 proteins levels by IF showed high
expression in proliferating IHs with predominantly
nuclear localization (Figure 5b). Involuting IHs also
showed HEY2 expression (Figure 5f), albeit with less
intensity of staining as that seen for proliferating IHs,
with the exception of sporadic stromal cells that stained
very strongly for HEY2 in involuting IHs (Figure 5f,
thick arrows). Although HEY2 was expressed in several
different cell types (Figure 5b, f), HEY2 proteins were
often found to be expressed in cells that were positive
for the endothelial cell marker CD31 (Figure 5c, g) and
one can clearly see the nuclear HEY2 in cells that show
CD31 cytoplasmic staining. HEY2 was not uniformly
present in all endothelial cells (Figure 5c, g, arrows),
suggesting that only a subset of IH endothelial cells
have Notch target, HEY2 expressed.
Evaluation of HEYL (Figure 6) protein levels showed
expression in multiple cell types but strong co-localiza-
tion of expression with NOTCH3 positive cells in both
proliferating (Figure 6c) and involuting (Figure 6g) IHs.
We have previously established NOTCH3 expression is
high in perivascular cells, CD133 positive components
of IHs (HemSCs and/or perivascular cells) and in iso-
lated HemSCs.[20] A subset of cells expressed HEYL
but not NOTCH3, shown as luminal cells with green
staining (HEYL) (Figure 6c, g). We thus conclude that
HEYL is predominantly expressed in NOTCH3 positive
cells of IHs.
Evaluation of HES1 expression showed strong nuclear
stain in a variety of cells in both proliferating and invo-
luting IHs (Figure 7). The HES1 staining was predomi-
nantly nuclear. A very low percentage of CD31+
endothelial cells co-stained for HES1 (Figure 7c, g, thin
arrows), indicating rare expression of HES1 in the
endothelial component of IH. In contrast, HES1 was
strongly expressed on perivascular cells, possibly peri-
cytes and HemSCs (thick arrows). This was clearly evi-
dent in involuting IHs, as strong nuclear signal was seen
on a subset of perivascular cells and cells within the
stromal compartment.
HES/HEY genes are activated by Notch signaling
Notch signaling is dependent on gamma-secretase clea-
vage to induce transcriptional activation of CSL and
thus drive Notch target gene expression, such as Hes
and Hey genes.[26] When HemSCs isolated from IHs
were treated with a Compound E, a gamma-secretase
inhibitor, the transcript levels of several HES/HEY genes
were reduced, indicating active Notch signaling main-
tained their expression (Figure 8). In HemSCs from the
H37 sample, all the tested HES/HEY genes (HEY1,
HEYL, HES1) transcript levels were downregulated by
GSI, with statistical significance (HEY1,p=0 . 0 1 ;HEYL
and HES1, p = 0.02). In sample H40 and H41, HemSCs
showed variable changes in HES/HEY transcript levels
(Figure 8), possibly due to low baseline HES/HEY tran-
script levels, compared to H37 HemSCs at baseline
(dark columns). Transcript levels of HEY2 also were low
at baseline (10% of that of HEY1 and HES1,a n d1 %o f
that for HEYL) and were difficult to evaluate after GSI
treatment (data not shown).
Taken together, these results demonstrated that the
Notch receptor is active and induces transcription of
downstream genes in HemSC. A subset of HES/HEY
genes responded to GSI treatment, and suppression of
Notch signaling activity reduced the transcript levels of
these genes. HES1 transcript levels were consistently
down-regulated by GSI, and HEY1 was variably down-
regulated. H37 sample, which had higher baseline HES/
HEY transcript levels than cells from other hemangioma
specimens, showed consistent and dramatic down-regu-
lation of HES/HEY expression in HemSCs.
Discussion
Notch proteins function as receptors on the cell surface
and are activated via interaction with Notch ligands,
which are also located on the cell surface. This juxta-
crine signaling leads to proteolytic cleavage of the
Notch ICD, catalyzed by the g-secretase complex. The
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Page 5 of 11Figure 3 Quantitative PCR results of HES and HEY genes in HemSCs and HemECs. Quantitative PCR results showed that HES1, HEY1,a n d
HEYL had higher transcript levels in HemSCs when compared to HemECs (*p<0.05, #p<0.01.) Gene transcript levels were expressed as relative to
beta-actin levels. Results were done in triplicates at least in 2 separate experiments and representative of 2 different cell lines. Statistical analysis
showed that the difference in transcript levels for HEY1 approached, but did not achieve, statistical significance (p = 0.08). However, the
transcript levels were statistically different between HemSCs and HemECs: Hey2 (p = 0.02), HeyL (p = 0.002), and Hes1 (p = 0.008).
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Page 6 of 11Figure 4 Immunofluorescence staining of CD31 and HEY1. Immunofluorescence staining CD31 (red) and HEY1 (green). There was no
appreciable staining in the involuting hemangioma specimen (bottom panels, d-f). However, HEY1 was present in the proliferating hemangioma
(a-c). Magnification, 40X.
Figure 5 Immunofluorescence staining of CD31 and HEY2. Immunofluorescence staining of CD31 (red) and HEY2 (green). Proliferating
hemangioma, panels a-c; involuting hemangioma, panels e-g. HEY2 staining was seen in the endothelial cell nucleui, whereas CD31 staining was
present in the cytoplasm. Therefore, while CD31 and HEY2 co-localized, the color did not overlap (thin arrows, panels c & g). Not all endothelial
cells (red cytoplasmic staining) co-stained with HEY2, and there were non-endothelial cells that were HEY2 positive (Figure 5f, thick arrows,
bright green). Magnification, 40X. Panels d, h: close up of panels 5c (proliferating hemangioma) and 5g (involuting hemangioma).
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Page 7 of 11intracellular domain of Notch (NICD) is released and
translocates into the cell nucleus, where it binds with
the CSL complex, leading to activation of target genes
such as the Hes/Hey family of transcription factors.
[27-29] As such, expression of Hes and Hey genes is
used to indicate that Notch signaling is functional in a
cell. Our previous study showed that Notch receptors
and ligands were expressed in HemSCs and HemECs
and we were interested in determining if Notch target
genes were expressed in these cells.
After analysis of eight members of the HES/HEY
family, we found that HES1, HEY1, HEY2 and HEYL
Figure 6 Immunofluorescence staining of NOTCH3 and HEYL. Immunofluorescence staining of NOTCH3 (green) and HEYL (red). Proliferating
hemangioma, panels a-c; involuting hemangioma, panels e-g. NOTCH3+ cells are located in the perivascular regions and co-localize with HEYL
(thick arrows, panels c & g). However, some endothelial cells also express HEYL (thin arrows, panels c & g). Magnification, 40×. Panels d, h: close
up of Figure 6c (proliferating hemangioma) and 6g (involuting hemangioma). There were luminal cells that stained for HEYL (green, thick arrows)
but not NOTCH3. The majority of HEYL positive cells co-localized with NOTCH3 (yellow).
Figure 7 Immunofluorescence staining of CD31 and HES1. Immunofluorescence staining of CD31 (green) and HES1 (red). Proliferating
hemangioma, panels a-c; involuting hemangioma, panels e-g. HES1 was expressed in HemSCs and were localized in the peri-vascular cells (thick
arrows, panels c & g). There were occasional endothelial cells that showed nuclear staining of HES1 and cytoplasmic staining of CD31 (thin
arrows, panels d & f). Magnification, 40×. Panels d, h: close up of Figure 7c (proliferating hemangioma) and 7g (involuting hemangioma). There
were occasional endothelial cells that expressed HES1 (red nuclei with green cytoplasm, thin arrows), while the majority of HES1+ cells (red
nuclei) were located in non-endothelial perivascular cells.
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Page 8 of 11are expressed in infantile hemangiomas. Moreover, simi-
lar to Notch receptors and ligands, there are differences
in transcript levels of these genes in the different cell
types. This may suggest specificity in Notch receptor
downstream signaling. Alternately, this specificity may
reflect that distinct HES/HEY genes are inherent to dif-
ferent cell types. Moreover, our immunofluorescence
results also parallel the Notch staining patterns pre-
viously reported, specifically, that endothelial cells and
perivascular cells stain for different Notch receptors.[20]
HES1 and HEYL were predominantly present on peri-
vascular cells, however, occasional endothelial cells also
expressed these transcription factors. HEY2, an endothe-
lial-associated protein, mostly co-localized to endothelial
cells (CD31+) in IHs, however there were occasional
non-endothelial, perivascular cells that showed HEY2
staining. Nonetheless, their presence suggests that
Notch signaling is active in these cells. Thus we con-
clude that HES1 and HEYL are expressed in perivascular
cells of IHs, whereas HEY2 is specific to the endothelial
component of IHs.
Gamma secretase inhibitors (GSI) block proteolytic
cleavage by g-secretase and thus prevent the release of
the NICD into the nucleus and subsequent downstream
steps. Notch functions are inhibited or attenuated by
GSI treatment, and it has been established that GSI
treatment can elicit angiogenic phenotypes associated
with loss of Notch function [30,31]. GSI treatment has
also been used to evaluate Notch function during
wound healing[32,33]. Moreover, HES1 transcripts in
melanoblasts[34] and HEY2 transcripts in human
mesenchymal stem cells[7] have been shown to be
decreased with gamma secretase inhibitor treatment.
However, it was not clear whether they also tested other
HES/HEY genes. As expected, treatment of our cells
with the GSI Compound E showed a decrease of HES/
HEY gene transcription. This suggests that not only are
Notch receptors and ligands expressed in HemSCs [20],
but that Notch signaling is occurring in HemSCs.
Since there was variability in transcript levels of the
different HES/HEY family proteins when HemSCs and
HemECs were compared, there may be target specificity
of HES/HEY genes in the Notch signaling pathway. In
HemSCs, where NOTCH3 is strongly expressed, HES1,
HEY1, and HEYL were expressed at levels 10 to 100
times to that of HEY2. It is conceivable that NOTCH3
specifically induces transcription of HES1, HEY1, and
HEYL, whereas transcription of HEY2 is activated by
other Notch receptors.
Measurement of these effector genes will provide a
tool for exploring Notch functions and relating that
expression to the patholobiology of IHs. Moreover, iden-
tification of transcription factors critical to hemangioma
development may provide multiple specific therapeutic
targets along the Notch signaling axis. In a recent study
by Boscolo et al, JAGGED-1 was found to be critical in
a stem-cell to pericyte differentiation in a murine model
of hemangioma.[35] Since JAGGED-1 exerts its activities
by signaling through Notch receptors, its crucial role in
regulating HemSC differentiation to pericytes suggests
t h a tt h eN o t c hp a t h w a yp l a y sar o l ei nh e m a n g i o m a
pathophysiology. Future studies will concentrate on the
Figure 8 Quantitative PCR results of HES/HEY genes after treatment with gamma secretase inhibitor. Transcript levels of HES/HEY genes
in HemSCs are changed with administration of a gamma secretase inhibitor (GSI), Compound E. HEY1 (left) transcripts were universally
decreased after GSI treatment, although only statistically significant for H37 (p = 0.01). HEYL (middle) transcripts were decreased in H37, (p =
0.02), but baseline transcript levels were too low for the other 2 cell lines for meaningful comparison. HES1 (right) transcripts were universally
decreased and were statistically significant for H37 (p = 0.02) and H41 (p = 0.03). It was not significant for H40 (p = 0.1).
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Page 9 of 11effects of functional manipulation of Notch signaling on
cell behavior, and more specific inhibition of specific
Notch receptors.
Conclusion
In summary, we surveyed HEY1, HEY2, HEYL, and
HES1, HES3, HES5, HES6, and HES7 expression in
infantile hemangiomas in this study. We showed that
HES1, HEY1, and HEYL are highly expressed in
HemSCs, whereas HEY2 is expressed in HemECs. More-
over, HES and HEY transcripts are affected by Com-
pound E, a gamma secretase with consistent down-
regulation of HES1, showing that NOTCH signaling
occurs in infantile hemangiomas.
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